Filing Details

Accession Number:
0001104659-23-100560
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-09-13 21:02:56
Reporting Period:
2023-09-11
Accepted Time:
2023-09-13 21:02:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1737953 Replimune Group Inc. REPL Biological Products, (No Disgnostic Substances) (2836) 822082553
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1744425 Pamela Esposito C/O Replimune Group, Inc.
500 Unicorn Park Drive
Woburn MA 01801
Chief Business Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-09-11 5,358 $3.30 268,794 No 4 M Direct
Common Stock Disposition 2023-09-11 5,358 $20.01 263,436 No 4 S Direct
Common Stock Acquisiton 2023-09-12 300 $3.30 263,736 No 4 M Direct
Common Stock Disposition 2023-09-12 300 $20.00 263,436 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2023-09-11 5,358 $0.00 5,358 $3.30
Common Stock Employee Stock Option (right to buy) Disposition 2023-09-12 300 $0.00 300 $3.30
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
86,333 2027-07-26 No 4 M Direct
86,033 2027-07-26 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
  2. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.05. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. Following the sales reported on this Form 4, the reporting person continues to beneficially own 263,436 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 491,569 shares of the Issuer's common stock, 376,774 of which are exercisable as of the date hereof.
  4. The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof.